Eosinophilic Inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Sep 23

PMID 36140282

Authors

Alessandro Vatrella

Angelantonio Maglio

Corrado Pelaia

Luigi Ciampo

Giulia Pelaia

Carolina Vitale

Affiliations

Soon will be listed here.

Abstract

Severe asthma is characterized by different endotypes driven by complex pathologic mechanisms. In most patients with both allergic and non-allergic asthma, predominant eosinophilic airway inflammation is present. Given the central role of eosinophilic inflammation in the pathophysiology of most cases of severe asthma and considering that severe eosinophilic asthmatic patients respond partially or poorly to corticosteroids, in recent years, research has focused on the development of targeted anti-eosinophil biological therapies; this review will focus on the unique and particular biology of the eosinophil, as well as on the current knowledge about the pathobiology of eosinophilic inflammation in asthmatic airways. Finally, current and prospective anti-eosinophil therapeutic strategies will be discussed, examining the reason why eosinophilic inflammation represents an appealing target for the pharmacological treatment of patients with severe asthma.

Citing Articles

Serum and urine eosinophil-derived neurotoxin (EDN) levels predict biologic response in severe asthma.

Kang Y, Kim H, Lee C, Jung J, Moon J, Park S World Allergy Organ J. 2025; 18(1):100990.

PMID: 39896201 PMC: 11784766. DOI: 10.1016/j.waojou.2024.100990.

Association of LPCAT1-rs8352 genetic variant with susceptibility and severity of pediatric bronchial asthma: a case-control study.

Mohany K, Gamal Y, Raheem Y BMC Pediatr. 2025; 25(1):68.

PMID: 39871194 PMC: 11770991. DOI: 10.1186/s12887-025-05425-x.

Regulation of Airway Epithelial-Derived Alarmins in Asthma: Perspectives for Therapeutic Targets.

Hansi R, Ranjbar M, Whetstone C, Gauvreau G Biomedicines. 2024; 12(10).

PMID: 39457624 PMC: 11505104. DOI: 10.3390/biomedicines12102312.

Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model.

Ambrosino P, Marcuccio G, Raffio G, Formisano R, Candia C, Manzo F Life (Basel). 2024; 14(7).

PMID: 39063652 PMC: 11278432. DOI: 10.3390/life14070899.

Phenotype to Treatable Traits-Based Management in Chronic Obstructive Pulmonary Disease.

Kumar A, Kant S, Niranjan V Cureus. 2024; 16(5):e60423.

PMID: 38882972 PMC: 11179745. DOI: 10.7759/cureus.60423.

References

Pelaia C, Vatrella A, Gallelli L, Lombardo N, Sciacqua A, Savino R . Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies. Drug Des Devel Ther. 2021; 15:1275-1284. PMC: 8001041. DOI: 10.2147/DDDT.S300988. View

Maas S, Breakefield X, Weaver A . Extracellular Vesicles: Unique Intercellular Delivery Vehicles. Trends Cell Biol. 2016; 27(3):172-188. PMC: 5318253. DOI: 10.1016/j.tcb.2016.11.003. View

Sverrild A, Hansen S, Hvidtfeldt M, Clausson C, Cozzolino O, Cerps S . The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur Respir J. 2021; 59(1). DOI: 10.1183/13993003.01296-2021. View

Boberg E, Johansson K, Malmhall C, Calven J, Weidner J, Radinger M . Interplay Between the IL-33/ST2 Axis and Bone Marrow ILC2s in Protease Allergen-Induced IL-5-Dependent Eosinophilia. Front Immunol. 2020; 11:1058. PMC: 7280539. DOI: 10.3389/fimmu.2020.01058. View

Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica G . Interleukin-5 in the Pathophysiology of Severe Asthma. Front Physiol. 2020; 10:1514. PMC: 6927944. DOI: 10.3389/fphys.2019.01514. View

McDowell P, Heaney L . Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy. 2019; 75(2):302-310. DOI: 10.1111/all.13966. View

Moore W, Bleecker E, Curran-Everett D, Erzurum S, Ameredes B, Bacharier L . Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007; 119(2):405-13. PMC: 2837934. DOI: 10.1016/j.jaci.2006.11.639. View

Younis U, Vallorz E, Addison K, Ledford J, Myrdal P . Preformulation and Evaluation of Tofacitinib as a Therapeutic Treatment for Asthma. AAPS PharmSciTech. 2019; 20(5):167. PMC: 6818719. DOI: 10.1208/s12249-019-1377-0. View

Nakamura Y, Ghaffar O, Olivenstein R, Taha R, Zhang D, Ray A . Gene expression of the GATA-3 transcription factor is increased in atopic asthma. J Allergy Clin Immunol. 1999; 103(2 Pt 1):215-22. DOI: 10.1016/s0091-6749(99)70493-8. View

10.

Dunican E, Fahy J . Asthma and corticosteroids: time for a more precise approach to treatment. Eur Respir J. 2017; 49(6). DOI: 10.1183/13993003.01167-2017. View

11.

Chatfield S, Thieblemont N, Witko-Sarsat V . Expanding Neutrophil Horizons: New Concepts in Inflammation. J Innate Immun. 2018; 10(5-6):422-431. PMC: 6785650. DOI: 10.1159/000493101. View

12.

Ohno I, Nitta Y, Yamauchi K, Hoshi H, Honma M, Woolley K . Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation. Am J Respir Cell Mol Biol. 1996; 15(3):404-9. DOI: 10.1165/ajrcmb.15.3.8810646. View

13.

Krug N, Hohlfeld J, Kirsten A, Kornmann O, Beeh K, Kappeler D . Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med. 2015; 372(21):1987-95. DOI: 10.1056/NEJMoa1411776. View

14.

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View

15.

Pelaia C, Vatrella A, Crimi C, Gallelli L, Terracciano R, Pelaia G . Clinical relevance of understanding mitogen-activated protein kinases involved in asthma. Expert Rev Respir Med. 2020; 14(5):501-510. DOI: 10.1080/17476348.2020.1735365. View

16.

Rogliani P, Ritondo B, Puxeddu E, Pane G, Cazzola M, Calzetta L . Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review. J Exp Pharmacol. 2020; 12:233-254. PMC: 7495344. DOI: 10.2147/JEP.S237480. View

17.

Pelaia G, Vatrella A, Cuda G, Maselli R, Marsico S . Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci. 2003; 72(14):1549-61. DOI: 10.1016/s0024-3205(02)02446-3. View

18.

Brightling C, Gaga M, Inoue H, Li J, Maspero J, Wenzel S . Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir Med. 2020; 9(1):43-56. DOI: 10.1016/S2213-2600(20)30412-4. View

19.

Lombardi C, Passalacqua G . Eosinophilia and diseases: clinical revision of 1862 cases. Arch Intern Med. 2003; 163(11):1371-3. DOI: 10.1001/archinte.163.11.1371-b. View

20.

Chen R, Smith S, Salter B, El-Gammal A, Oliveria J, Obminski C . Allergen-induced Increases in Sputum Levels of Group 2 Innate Lymphoid Cells in Subjects with Asthma. Am J Respir Crit Care Med. 2017; 196(6):700-712. DOI: 10.1164/rccm.201612-2427OC. View